References

1. Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.-D.; Coopersmith, C.M.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315, 801–810.
2. Cutuli, S.; De Pascale, G.; Antonelli, M. ’σήψις’ yesterday, sepsis nowadays: What’s changing? J. Thorac. Dis. 2017, 9, E166–E167.
3. De Pascale, G.; Cutuli, S.; Pennisi, M.; Antonelli, M. The role of mannose-binding lectin in severe sepsis and septic shock. Mediat. Inflamm. 2013, 2013, 625803.
4. Davenport, E.; Burnham, K.L.; Radhakrishnan, J.; Humburg, P.; Hutton, P.; Mills, T.C.; Rautanen, A.; Gordon, A.C.; Garrard, C.; Hill, A.V.S.; et al. Genomic landscape of the individual host response and outcomes in sepsis: A prospective cohort study. Lancet Respir. Med. 2016, 4, 259–271.
5. Cutuli, S.L.; Carelli, S.; De Pascale, G. The gut in critically ill patients: How unrecognized “7th organ dysfunction” feeds sepsis. Minerva Anestesiol. 2020, 86, 595–597.
6. Cutuli, S.L.; De Maio, F.; De Pascale, G.; Grieco, D.L.; Monzo, F.R.; Carelli, S.; Tanzarella, E.S.; Pintaudi, G.; Piervincenzi, E.; Cascarano, L.; et al. COVID-19 influences lung microbiota dynamics and favors the emergence of rare infectious diseases: A case report of Hafnia Alvei pneumonia. J. Crit. Care 2021, 64, 173–175.
7. Hotchkiss, R.; Moldawer, L.; Opal, S.; Reinhart, K.; Turnbull, I.; Vincent, J. Sepsis and septic shock. Nat. Rev. Dis. Primers 2016, 2, 16045.
8. Boomer, J.; Green, J.; Hotchkiss, R. The changing immune system in sepsis: Is individualized immuno-modulatory therapy the answer? Virulence 2014, 5, 45–56.
9. Marshall, J.C.; Foster, D.M.; Vincent, J.; Cook, D.J.; Cohen, J.; Dellinger, R.P.; Opal, S.M.; Abraham, E.H.; Brett, S.J.; Smith, T.J.; et al. Diagnostic and Prognostic Implications of Endotoxemia in Critical Illness: Results of the MEDIC Study. J. Infect. Dis. 2004, 190, 527–534.
10. Rubartelli, A.; Lotze, M.T. Inside, outside, upside down: Damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007, 28, 429–436.
11. Binnie, A.; Tsang, J.L.; Hu, P.; Carrasqueiro, G.; Castelo-Branco, P.; Dos Santos, C.C. Epigenetics of Sepsis. Crit. Care Med. 2020, 48, 745–756.
12. Wolff, N.S.; Hugenholtz, F.; Wiersinga, W.J. The emerging role of the microbiota in the ICU. Crit. Care 2018, 22, 78.
13. Kitsios, G.D.; Morowitz, M.J.; Dickson, R.P.; Huffnagle, G.B.; McVerry, B.J.; Morris, A. Dysbiosis in the intensive care unit: Microbiome science coming to the bedside. J. Crit. Care 2017, 38, 84–91.
14. Yadav, H.; Cartin-Ceba, R. Balance between Hyperinflammation and Immunosuppression in Sepsis. Semin. Respir. Crit. Care Med. 2016, 37, 042–050.
15. Vincent, J.; Moreno, R.; Takala, J.; Willatts, S.; Mendonça, A.D.; Bruining, H.; Reinhart, C.K.; Suter, P.M.; Thijs, L.G. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996, 22, 707–710.
16. Ferreira, F.L.; Bota, D.P.; Bross, A.; Mélot, C.; Vincent, J.-L. Serial Evaluation of the SOFA Score to Predict Outcome in Critically Ill Patients. JAMA 2001, 286, 1754–1758.
17. Seymour, C.; Liu, V.; Iwashyna, T.; Brunkhorst, F.; Rea, T.; Scherag, A.; Rubenfeld, G.; Kahn, J.M.; Shankar-Hari, M.; Singer, M.; et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315, 762–774.
18. Rhodes, A.; Evans, L.E.; Alhazzani, W.; Levy, M.M.; Antonelli, M.; Ferrer, R.; Kumar, A.; Sevransky, J.E.; Sprung, C.L.; Nunnally, M.E.; et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017, 43, 304–377.
19. Mathias, B.; Szpila, B.E.; Moore, F.A.; Efron, P.A.; Moldawer, L.L. A Review of GM-CSF Therapy in Sepsis. Medicine 2015, 94, e2044.
20. Döcke, W.; Randow, F.; Syrbe, U.; Krausch, D.; Asadullah, K.; Reinke, P.; Volk, H.-D.; Kox, W. Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment. Nat. Med. 1997, 3, 678–681.
21. Piguet, P.F.; Grau, G.E.; De Kossodo, S. Role of Granulocyte-Macrophage Colony-Stimulating Factor in Pulmonary Fibrosis Induced in Mice by Bleomycin. Exp. Lung Res. 1993, 19, 579–587.
22. Serafini, P.; Carbley, R.; Noonan, K.A.; Tan, G.; Bronte, V.; Borrello, I. High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells. Cancer Res. 2004, 64, 6337–6343.
23. Shindo, Y.; Fuchs, A.G.; Davis, C.G.; Eitas, T.; Unsinger, J.; Burnham, C.-A.D.; Green, J.M.; Morre, M.; Bochicchio, G.V.; Hotchkiss, R.S. Interleukin 7 immunotherapy improves host immunity and survival in a two-hit model of Pseudomonas aeruginosa pneumonia. J. Leukoc. Biol. 2017, 101, 543–554.
24. Unsinger, J.; Burnham, C.-A.D.; McDonough, J.; Morre, M.; Prakash, P.S.; Caldwell, C.C.; Dunne, W.M.; Hotchkiss, R.S. Interleukin-7 Ameliorates Immune Dysfunction and Improves Survival in a 2-Hit Model of Fungal Sepsis. J. Infect. Dis. 2012, 206, 606–616.
25. Rittirsch, D.; Flierl, M.; Nadeau, B.; Day, D.; Huber-Lang, M.; Mackay, C.R.; Zetoune, F.S.; Gerard, N.P.; Cianflone, K.; Köhl, J.; et al. Functional roles for C5a receptors in sepsis. Nat. Med. 2008, 14, 551–557.
26. Oncul, S.; Afshar-Kharghan, V. The interaction between the complement system and hemostatic factors. Curr. Opin. Hematol. 2020, 27, 341–352.
27. Vincent, J.; Francois, B.; Zabolotskikh, I.; Daga, M.K.; Lascarrou, J.-B.; Kirov, M.Y.; Pettilä, V.; Wittebole, X.; Meziani, F.; Mercier, E.; et al. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients with Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. JAMA 2019, 321, 1993–2002.
28. Ranieri, V.M.; Thompson, B.T.; Barie, P.S.; Dhainaut, J.-F.; Douglas, I.S.; Finfer, S.; Gårdlund, B.; Marshall, J.C.; Rhodes, A.; Artigas, A.; et al. Drotrecogin Alfa (Activated) in Adults with Septic Shock. N. Engl. J. Med. 2012, 366, 2055–2064.
29. Shankar-Hari, M.; Spencer, J.; Sewell, W.; Rowan, K.M.; Singer, M. Bench-to-bedside review: Immunoglobulin therapy for sepsis -biological plausibility from a critical care perspective. Crit. Care 2012, 16, 206–214.
30. Alejandria, M.M.; Lansang MA, D.; Dans, L.F.; Mantaring, J.B., III. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst. Rev. 2013, 2013, CD001090.
31. Laupland, K.B.; Kirkpatrick, A.W.; Delaney, A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta-analysis. Crit. Care Med. 2007, 35, 2686–2692.
32. Peeters, B.; Langouche, L.; Berghe, G.V.D. Adrenocortical Stress Response during the Course of Critical Illness. Compr. Physiol. 2017, 8, 283–298.
33. Heming, N.; Sivanandamoorthy, S.; Meng, P.; Bounab, R.; Annane, D. Immune Effects of Corticosteroids in Sepsis. Front. Immunol. 2018, 9, 1736.
34. Gibbison, B.; López-López, J.A.; Higgins, J.P.T.; Miller, T.; Angelini, G.D.; Lightman, S.L.; Annane, D. Corticosteroids in septic shock: A systematic review and network meta-analysis. Crit. Care 2017, 21, 1–8.
35. Rygård, S.L.; Butler, E.; Granholm, A.; Møller, M.H.; Cohen, J.; Finfer, S.; Perner, A.; Myburgh, J.; Venkatesh, B.; Delaney, A. Low-dose corticosteroids for adult patients with septic shock: A systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018, 44, 1003–1016.
36. Torres, A.; Sibila, O.; Ferrer, M.; Polverino, E.; Mendendez, R.; Mensa, J.; Gabarrus, A.; Sellares, J.; Restrepo, M.; Anzueto, A.; et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial. Acute Critical Care 2015, 46, 677–686.
37. Recovery Collaborative Group; Horby, P.; Lim, W.S.; Emberson, J.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; et al. Dexamethasone in Hospitalized Patients with Covid-19—Preliminary Report. N. Engl. J. Med. 2021, 384, 693–704, (online ahead of print).
38. Metlay, J.P.; Waterer, G.W.; Long, A.C.; Anzueto, A.; Brozek, J.; Crothers, K.; Cooley, L.A.; Dean, N.C.; Fine, M.J.; Flanders, S.A.; et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the american thoracic society and infectious diseases society of America. Am. J. Respir. Crit. Care Med. 2019, 200, e45–e67.
39. Hayakawa, M.; Katabami, K.; Wada, T.; Sugano, M.; Hoshino, H.; Sawamura, A.; Gando, S. Sivelestat (Selective Neutrophil Elastase Inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome and disseminated intravascular coagulation patients. Shock 2010, 33, 14–18.
40. Nakamori, Y.; Park, E.J.; Shimaoka, M. Immune Deregulation in Sepsis and Septic Shock: Reversing Immune Paralysis by Targeting PD-1/PD-L1 Pathway. Front. Immunol. 2021, 11, 624279.
41. Ryter, S.W. Therapeutic Potential of Heme Oxygenase-1 and Carbon Monoxide in Acute Organ Injury, Critical Illness, and Inflammatory Disorders. Antioxidants 2020, 9, 1153.
42. Bellomo, R.; Kellum, J.A.; Ronco, C.; Wald, R.; Martensson, J.; Maiden, M.; Bagshaw, S.M.; Glassford, N.J.; Lankadeva, Y.; Vaara, S.T.; et al. Acute kidney injury in sepsis. Intensive Care Med. 2017, 43, 816–828.
43. Cutuli, S.; Grieco, D.; De Pascale, G.; Antonelli, M. Hemadsorption. Curr. Opin. Anaesthesiol. 2021, 34, 113–118, (online ahead of print).
44. Douvris, A.; Malhi, G.; Hiremath, S.; McIntyre, L.; Silver, S.; Bagshaw, S.M.; Wald, R.; Ronco, C.; Sikora, L.; Weber, C.; et al. Interventions to prevent hemodynamic instability during renal replacement therapy in critically ill patients: A systematic review. Crit. Care 2018, 22, 41.
45. Kushimoto, S.; Gando, S.; Saitoh, D.; Mayumi, T.; Ogura, H.; Fujishima, S.; Araki, T.; Ikeda, H.; Kotani, J.; Miki, Y.; et al. The impact of body temperature abnormalities on the disease severity and outcome in patients with severe sepsis: An analysis from a multicenter, prospective survey of severe sepsis. Crit. Care 2013, 17, R271.
46. Malard, B.; Lambert, C.; Kellum, J. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med. Exp. 2018, 6, 12.
47. Broman, M.E.; Hansson, F.; Vincent, J.-L.; Bodelsson, M. Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: A randomized crossover double-blind study. PLoS ONE 2019, 14, e0220444.
48. Villa, G.; Romagnoli, S.; De Rosa, S.; Greco, M.; Resta, M.; Montin, D.P.; Prato, F.; Patera, F.; Ferrari, F.; Rotondo, G.; et al. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: A pilot study. Crit. Care 2020, 24, 1–13.
49. Cascarano, L.; Cutuli, S.L.; Pintaudi, G.; Tanzarella, E.S.; Carelli, S.; Anzellotti, G.; Grieco, D.L.; DE Pascale, G.; Antonelli, M. Extracorporeal immune modulation in COVID-19 induced immune dysfunction and secondary infections: The role of oXiris® membrane. Minerva Anestesiol. 2021, 87. (online ahead of print).
50. Harm, S.; Schildböck, C.; Hartmann, J. Cytokine Removal in Extracorporeal Blood Purification: An in vitro Study. Blood Purif. 2020, 49, 33–43.
51. Schädler, D.; Pausch, C.; Heise, D.; Meier-Hellmann, A.; Brederlau, J.; Weiler, N.; Marx, G.; Putensen, C.; Spies, C.; Jörres, A.; et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. PLoS ONE 2017, 12, e0187015.
52. Seffer, M.-T.; Cottam, D.; Forni, L.G.; Kielstein, J.T. Heparin 2.0: A New Approach to the Infection Crisis. Blood Purif. 2021, 50, 28–34, (online ahead of print).
53. Livigni, S.; Bertolini, G.; Rossi, C.; Ferrari, F.; Giardino, M.; Pozzato, M.; Remuzzi, G. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial. BMJ Open 2014, 4, e003536.
54. Ankawi, G.; Neri, M.; Zhang, J.; Breglia, A.; Ricci, Z.; Ronco, C. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: The promises and the pitfalls. Crit. Care 2018, 22, 262.
55. Morgera, S.; Slowinski, T.; Melzer, C.; Sobottke, V.; Vargas-Hein, O.; Volk, T.; Zuckermann-Becker, H.; Wegner, B.; Müller, J.M.; Baumann, G.; et al. Renal replacement therapy with high-cutoff hemofilters: Impact of convection and diffusion on cytokine clearances and protein status. Am. J. Kidney Dis. 2004, 43, 444–453.
56. Haase, M.; Bellomo, R.; Baldwin, I.; Haase-Fielitz, A.; Fealy, N.; Davenport, P.; Morgera, S.; Goehl, H.; Storr, M.; Boyce, N.; et al. Hemodialysis Membrane With a High-Molecular-Weight Cutoff and Cytokine Levels in Sepsis Complicated by Acute Renal Failure: A Phase 1 Randomized Trial. Am. J. Kidney Dis. 2007, 50, 296–304.
57. Morgera, S.; Haase, M.; Kuss, T.; Vargas-Hein, O.; Zuckermann-Becker, H.; Melzer, C.; Krieg, H.; Wegner, B.; Bellomo, R.; Neumayer, H.-H. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit. Care Med. 2006, 34, 2099–2104.
58. Morgera, S.; Haase, M.; Rocktäschel, J.; Böhler, T.; Vargas-Hein, O.; Melzer, C.; Krausch, D.; Kox, W.J.; Baumann, G.; Beck, W.; et al. Intermittent High-Permeability Hemofiltration Modulates Inflammatory Response in Septic Patients with Multiorgan Failure. Nephron Clin. Pract. 2003, 94, c75–c80.
59. Morgera, S.; Rocktäschel, J.; Haase, M.; Lehmann, C.; Von Heymann, C.; Ziemer, S.; Priem, F.; Hocher, B.; Göhl, H.; Kox, W.J.; et al. Intermittent high permeability hemofiltration in septic patients with acute renal failure. Intensive Care Med. 2003, 29, 1989–1995.
60. Antonelli, M.; Bello, G.; Maviglia, R.; Cutuli, S.; Ronco, C.; Cruz, D.; Ranieri, V.M.; Martin, E.; Fumagalli, R.; Monti, G.; et al. Polymyxin B hemoperfusion in clinical practice: The picture from an unbound collaborative registry. Blood Purif. 2014, 37, 22–25.
61. Cutuli, S.L.; Artigas, A.; Fumagalli, R.; Monti, G.; Ranieri, V.M.; Ronco, C.; Antonelli, M. Polymyxin-B hemoperfusion in septic patients: Analysis of a multicenter registry. Ann. Intensiv. Care 2016, 6, 77.
62. Fujii, T.; Ganeko, R.; Kataoka, Y.; Furukawa, T.; Featherstone, R.; Doi, K.; Vincent, J.; Pasero, D.; Robert, R.; Ronco, C.; et al. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: A systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018, 44, 167–178.
63. Chang, T.; Tu, Y.K.; Lee, C.T.; Chao, A.; Huang, C.H.; Wang, M.J.; Yeh, Y.C. Effects of Polymyxin B Hemoperfusion on Mortality in Patients with Severe Sepsis and Septic Shock: A Systemic Review, Meta-Analysis Update, and Disease Severity Subgroup Meta-Analysis. Crit. Care Med. 2017, 45, e858–e864.
64. Romaschin, A.D.; Obiezu-Forster, C.V.; Shoji, H.; Klein, D.J. Novel Insights into the Direct Removal of Endotoxin by Polymyxin B Hemoperfusion. Blood Purif. 2017, 44, 193–197.
65. Srisawat, N.; Tungsanga, S.; Lumlertgul, N.; Komaenthammasophon, C.; Peerapornratana, S.; Thamrongsat, N.; Tiranathanagul, K.; Praditpornsilpa, K.; Eiam-Ong, S.; Tungsanga, K.; et al. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients. Crit. Care 2018, 22, 1–10.
66. De Rosa, S.; Cutuli, S.; Ferrer, R.; Antonelli, M.; Ronco, C.; the COVID-19 EUPHAS2 Collaborative Group. Polymyxin B hemoperfusion in COVID-19 Patients with endotoxic shock: Case Series from EUPHAS II registry. Artif. Organs 2020. (online ahead of print).
67. Scicluna, B.P.; Vught, L.A.; Zwinderman, A.H.; Wiewel, M.A.; Davenport, E.E.; Burnham, K.L.; Nürnberg, P.; Schultz, M.J.; Horn, J.; Cremer, O.L.; et al. Classification of patients with sepsis according to blood genomic endotype: A prospective cohort study. Lancet Respir. Med. 2017, 5, 816–826.
68. Celi, L.; Mark, R.; Stone, D.; Montgomery, R. “Big data” in the intensive care unit. Closing the data loop. Am. J. Respir. Crit. Care Med. 2013, 187, 1157–1160.
69. Mohammed, A.; Van Wyk, F.; Chinthala, L.K.; Khojandi, A.; Davis, R.L.; Coopersmith, C.M.; Kamaleswaran, R. Temporal Differential Expression of Physiomarkers Predicts Sepsis in Critically Ill Adults. Shock 2020. (online ahead of print).